To evaluate the efficacy and safety of ALN-RSV01 plus standard of care in RSV infected lung transplant patients

Inclusion Criteria:

• Single or bilateral lung transplant recipients
• Confirmed RSV infection
• Greater than 90 days post current lung transplant
• Rejection free for a minimum of 30 days

Exclusion Criteria:

• Known viral, bacterial, or fungal respiratory co-infection at the time of RSV diagnosis
• Bronchiolitis obliterans syndrome (BOS) Grade 3 or any BOS with FEV1 that has not been stable for at least 3 months
• Use of alemtuzumab within 9 months prior to screening, anti-thymocyte globulin (ATG) within 90 days of screening or prednisone or equivalent as maintenance therapy
• Active treatment for acute graft rejection